Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9